Neurology; a pain or a headache for investors?
Indications in neuroscience and multiple sclerosis : the past;
the issues; the future. Andy Smith casts an investors eye at
neurological disorders, particularly Alzheimers disease,
Guillian-Barre Syndrome and multiple sclerosis. He looks at why
investors find this a difficult area to predict clinical success
and explores drug discovery process, interferons and new
A series of expert analysis and commentary on the Life Science sector. Join the discussion; share your views.